Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Not applicable

Attention Modulation of Local and Global Inhibition Mechanisms

NCT04279158 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2022-11-26
Last updated
2026-01-20

Condition(s) studied

Optical Phenomena

Investigational drug(s) / intervention(s)

experience 1 "The negative priming task"experience 2 "Stop signal task"experience 3 "Anti-saccades"

experience 1 "The negative priming task": The targets are presented to the subject on a computer screen. The subject must make an eye or hand movement toward the target and ignore the distracters.

experience 2 "Stop signal task": The targets are presented to the subject on a computer screen. The subject must make an eye movement towards this target. Sometimes a stop signal will appear and the subject will have to avoid to look at the target

experience 3 "Anti-saccades": The targets are presented to the subject on a computer screen. The subject must make an eye movement toward this target. Sometimes an instruction will ask the subject to look at the opposite of the target

Study summary

Human behavior is both flexible and adapted to the environmental context through inhibition capabilities; the investigator control the subject's behavior by repressing inappropriate responses and selecting, among several possibilities, those that are appropriate. These mechanisms are not independent of attentional control. Attention acts as a selection filter for the investigator's behavior. This leads us to hypothesize that attention modulates the mechanisms of inhibition. Nevertheless, the different brain structures involved, as well as mechanisms underlying the interaction between inhibition and attention remain largely unknown.

Previous research has suggested that inhibition requires selective attention and, conversely, attentional mechanisms would result in the "deselection", or inhibition, of objects in space or irrelevant actions. Reconciling the literature on attention with the one on inhibition appears fundamental for the understanding of the instance to which the mechanisms of inhibition and the cognitive processes interact. Therefore, the goal of this research project will be to investigate how inhibition mechanisms are implemented in the brain and, in more detail, what determines the type of resulting inhibitory control: spatially localized or global. The investigator will test 3 different patient groups (optic ataxia, hemispatial neglect and attention-deficit hyperactivity disorder) compared to control.

In conclusion, this research project will aim to develop a theoretical model of the interaction between attentional control and inhibition mechanisms in order to improve diagnostic and rehabilitation tools in the future.

Eligibility

Sex
ALL
Min age
8 Years
Max age
75 Years
Healthy volunteers
Accepted
All patients and healthy subjects: Inclusion Criteria: * male and female, age from 18 to 75 years included * normal vision or corrected vision * covered by social security * signed written informed consent Exclusion Criteria: * unable to comply with requirements of the study (neurological, psychiatric, sensory or motor troubles) * adults under legal protection Patient with hemispatial neglect: Inclusion Criteria: * After a stroke (\> 1 month ago), presence of a neurological impairment documented by brain imaging (standard of care) and by clinical symptoms. * The diagnosis will be dissociated from hemianopia by perimetry. The hemispatial neglect consists of a lack of perception and responsiveness concerning the controlesional visual hemifield. Patient with optic ataxia: * After a stroke (\> 1 month ago), presence of neurological injury in parietal cortex only, supported by a standard of care cerebral MRI * Present optic ataxia symptoms (The OA consists of pointing errors with the hand contralateral to the lesion (hand effect) and / or to visual targets presented in the field contralateral to the lesion (field effect)). Patient (adult and children) with attention-deficit hyperactivity disorder: * present a diagnosis of ADHD subtype inattention or impulse / hyperactivity as established by a neuropsychologist. * Children will be between 8 and 18 years old * Adults will be between 18 and 75 years old. * Participants will not report any comorbid learning disabilities to ADHD. For minors: \- Having obtained the written consent of the legal representative(s) Healthy subjects Inclusion Criteria: \- no known neurological injury

Primary outcome measure(s)

  • error rate — at the end of the simulation passage, an average of 3 years
    The investigator calculate the number of right and wrong answers (a correct answer is a saccade carried out when it is necessary and by reaching the target; a false answer is a saccade made at the wrong time and / or not reaching the target) to obtain the error rate.

Trial sites (1)

FacilityCityRegionStatus
Centre de Recherche en Neuroscience de Lyon Bron France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04279158 on ClinicalTrials.gov ↗ ← All trials in France